Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Infection by Virus Capsid Destabilization
- 1 January 2011
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 85 (1), 542-549
- https://doi.org/10.1128/jvi.01406-10
Abstract
Human immunodeficiency virus type 1 (HIV-1) infection is dependent on the proper disassembly of the viral capsid, or “uncoating,” in target cells. The HIV-1 capsid consists of a conical multimeric complex of the viral capsid protein (CA) arranged in a hexagonal lattice. Mutations in CA that destabilize the viral capsid result in impaired infection owing to defects in reverse transcription in target cells. We describe here the mechanism of action of a small molecule HIV-1 inhibitor, PF-3450074 (PF74), which targets CA. PF74 acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells. We show that PF74 binds specifically to HIV-1 particles, and substitutions in CA that confer resistance to the compound prevent binding. A single point mutation in CA that stabilizes the HIV-1 core also conferred strong resistance to the virus without inhibiting compound binding. Treatment of HIV-1 particles or purified cores with PF74 destabilized the viral capsid in vitro . Furthermore, the compound induced the rapid dissolution of the HIV-1 capsid in target cells. PF74 antiviral activity was promoted by binding of the host protein cyclophilin A to the HIV-1 capsid, and PF74 and cyclosporine exhibited mutual antagonism. Our data suggest that PF74 triggers premature HIV-1 uncoating in target cells, thereby mimicking the activity of the retrovirus restriction factor TRIM5α. This study highlights uncoating as a step in the HIV-1 life cycle that is susceptible to small molecule intervention.Keywords
This publication has 37 references indexed in Scilit:
- Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2010
- Flexible Use of Nuclear Import Pathways by HIV-1Cell Host & Microbe, 2010
- Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase InhibitorAntimicrobial Agents and Chemotherapy, 2009
- Cyclophilin A-Dependent Restriction of Human Immunodeficiency Virus Type 1 Capsid Mutants for Infection of Nondividing CellsJournal of Virology, 2008
- A Cell-penetrating Helical Peptide as a Potential HIV-1 InhibitorJournal of Molecular Biology, 2008
- The structural biology of HIV assemblyCurrent Opinion in Structural Biology, 2008
- Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131Antimicrobial Agents and Chemotherapy, 2008
- Structure of the Antiviral Assembly Inhibitor CAP-1 Complex with the HIV-1 CA ProteinJournal of Molecular Biology, 2007
- Cyclophilin A, TRIM5, and Resistance to Human Immunodeficiency Virus Type 1 InfectionJournal of Virology, 2007
- The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeysNature, 2004